One-year anniversary surprise: 46brooklyn receives tax-exempt non-profit status!

In the context of life, one year can pass in a flash. In the context of 46brooklyn's life, one year can feel like a lifetime.

This month, 46brooklyn Research has officially reached one full year of existence. We've come a long way since our launch in August 2018, where we released our first two interactive drug pricing visualizations (Drug Pricing Dashboard and Medicaid Drug Pricing Heat Map) and our first drug pricing report on generic Gleevec entitled, "The Cancerous Design of the U.S. Drug Pricing System."

After poking and prodding our work and datasets, Bob Herman at Axios did a great write-up on our launch at the time, and since then, it has been a fun and exciting ride.

We began as two pharmacy guys huddled in coffee shops at odd hours, hoping to shed light on broken components of the prescription drug supply chain. Over time, as 46brooklyn began making its way around industry, media, and government circles, we got to meet a lot of amazing people working to make sense of this crazy system. We set out to teach what we had learned during our time in pharmacy, but it turned out that we probably have learned much more than we've taught.

Today, we've now published over a dozen original research works, conduct ongoing drug pricing analytics projects, created ten interactive drug pricing dashboards, begun a video series, recorded a webinar for benefits experts, and have been featured in nearly 50 news stories.

Most importantly, we are proud to see that our work has elevated the level of understanding and dialogue around the prescription drug supply chain, and we could not be more appreciative of our followers' appetite for more.

We have big plans for year 2, and we're excited to continue the journey.

And with that journey, we are pleased to announce a more formalized organizational structure for 46brooklyn. This month, we received word from the IRS that 46brooklyn Research is now officially recognized as a 501(c)(3) Public Charity. As a tax-exempt non-profit organization, our main goal remains the same: to improve the accessibility and usability of U.S. drug pricing data.

Our hope is that better awareness and education will help improve the accountability of our prescription drug supply chain and, in time, lead to the much-needed simplification of how drugs are priced.

If you are interested in supporting our efforts, all monetary donations to 46brooklyn Research (EIN #83-3213092) are now tax deductible to the fullest extent allowed by tax laws. Please check with your financial advisor if you have more questions about that.

We thank you for your continued interest and support, and we hope to have an even bigger and better year than our first. We are passionately committed to bringing transparency and accountability to the prescription drug supply chain.